Publications
The following video explains the comprehensive body of evidence reported in our most recent publication in Science Translational Medicine (Feb 2026)
Our scientific publications
February 4, 2026
Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114
Published in Science Translational Medicine
In collaboration between Leyden Labs and Harvard University, University of Kent and University of Greenwich, University of Sheffield, and Beth Israel Deaconess Medical Center
December 7, 2025
Preventing SARS-CoV-2 superspreading events with antiviral intranasal sprays
Published in Journal of Theoretical Biology
In collaboration between Leyden Labs and Imperial College London, University of Sussex, and Harvard University
June 13, 2025
Data dashboard to support meta-analyses on influenza vaccine effectiveness across regions, influenza seasons and outcomes
Preprint published on medRxiv
April 08, 2025
Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection
Published in Scientific Reports
In collaboration between Leyden Labs and Harvard University, Wageningen University & Research, University of Kent and University of Greenwich, The Ragon Institute, and Maastricht University
February 15, 2024
A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration
Published in Scientific Reports
In collaboration between Leyden Labs and Harvard University, University of Manchester, University of Sussex, and University of Kent and University of Greenwich
February 04, 2023
SARS‑CoV‑2 elicits non‑sterilizing immunity and evades vaccine‑induced immunity: implications for future vaccination strategies
Published in European Journal of Epidemiology
In collaboration between Leyden Labs and Harvard University, University of Manchester, Imperial College London, and the Ragon Institute
November 02, 2022
The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection
Published in Frontiers in Virology
In collaboration between Leyden Labs and Harvard University, Maastricht University, and the Ragon Institute
October 30, 2022
Exploring the role of antiviral nasal sprays in the control of emerging respiratory infections in the community
Published in Infectious Diseases and Therapy
In collaboration between Leyden Labs and Imperial College London, Harvard University, and the Ragon Institute
OUR NEW APPROACH | OUR TEAM | JOIN OUR MISSION | NEWS | CAREERS
Leyden Laboratories B.V.
Leiden Laboratory
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands
Leyden Labs Asia Pte. Ltd.
79 Science Park Drive
#04-05, Cintech IV
Singapore 118264
© Leyden Labs, 2025 | Privacy Statement | Design by Ape to Zebra
